Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 89.65 USD 2.66% Market Closed
Market Cap: 5.6B USD
Section:
 

Relative Value

The Relative Value of one PTGX stock under the Base Case scenario is hidden USD. Compared to the current market price of 89.65 USD, Protagonist Therapeutics Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PTGX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

26.8
P/S
P/S
Price to Sales
26.8
vs History
38
vs Industry
51
Median 3Y
11.8
Median 5Y
17.5
Industry
7.9
Forward
84.7
More Details
121.9
P/E
P/E
Price to Earnings
121.9
vs History
0
vs Industry
10
Median 3Y
8.6
Median 5Y
-5.4
Industry
24
Forward
-45.4
More Details
85.5
P/OCF
P/OCF
Price to OCF
85.5
vs History
3
vs Industry
10
Median 3Y
-3.7
Median 5Y
-8.1
Industry
21.6
More Details
87.9
P/FCFE
P/FCFE
Price to FCFE
87.9
vs History
3
vs Industry
9
Median 3Y
-3.7
Median 5Y
-8
Industry
23.7
More Details
8.7
P/B
P/B
Price to Book Value
8.7
vs History
0
vs Industry
20
Median 3Y
4.1
Median 5Y
4.2
Industry
3.4
More Details
24
EV/S
EV/S
Enterprise Value to Sales
24
vs History
26
vs Industry
45
Median 3Y
7.2
Median 5Y
13.3
Industry
8.3
Forward
76
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
245.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
245.6
vs History
0
vs Industry
11
Median 3Y
7.6
Median 5Y
-3.5
Industry
6.7
Forward
-33.9
More Details
264.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
264.2
vs History
0
vs Industry
10
Median 3Y
7.7
Median 5Y
-3.5
Industry
7.2
Forward
-32.9
More Details
76.7
EV/OCF
EV/OCF
Enterprise Value to OCF
76.7
vs History
1
vs Industry
11
Median 3Y
-1.1
Median 5Y
-5.4
Industry
8.2
More Details
78.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
78.8
vs History
1
vs Industry
8
Median 3Y
-1.1
Median 5Y
-5.4
Industry
6.7
More Details
41.9
EV/IC
EV/IC
Enterprise Value to IC
41.9
vs History
41
vs Industry
22
Median 3Y
35.5
Median 5Y
35.5
Industry
5.7
More Details

Multiples Across Competitors

PTGX Competitors Multiples
Protagonist Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
5.6B USD 26.8 121.9 245.6 264.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
399.6B USD 6.7 170.2 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
177.5B USD 4.9 25.3 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD 5.3 16.5 15.7 17.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD 18.8 1 385.9 182.8 221.7
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
47.2B EUR 15.2 35.8 62 63.7
P/E Multiple
Earnings Growth PEG
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 202.8
121.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 385.9
N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.8
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBITDA: 65.5
245.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.8
N/A N/A
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
62
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBIT: 73.6
264.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
13%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
221.7
N/A N/A
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.7
N/A N/A

See Also

Summary
PTGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
PTGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PTGX stock valuation using valuation multiples.
Wall Street Estimates
PTGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PTGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.